Press Releases / Notices

The company’s press releases sometimes carry information on pharmaceutical drugs and products in the pipeline. Under no circumstances is such information provided to promote or advertise these products or offer medical advice.

NEWS 2013

September 26, 2013 Pharmaceuticals

Launch of "LUNABELL® tablets ULD" for dysmenorrhea

 Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan, President: Shigenobu Maekawa) today announced the launch of “LUNABELL® tablets ULD” for the treatment of dysmenorrhea.

 “LUNABELL® tablets ULD” is a female hormone agent that contains the smallest amount of ethinyl estradiol (EE) in Japan. Nobelpharma Co., Ltd. (Headquarters: Tokyo, Japan, President: Jin Shiomura) developed this product and received the marketing authorization for the treatment of dysmenorrhea. It is the world’s first product which was approved for dysmenorrhea and contains 1 mg of norethisterone and 0.02 mg of EE.
Nippon Shinyaku is currently marketing “LUNABELL® tablets LD” which contains 1 mg of norethisterone and 0.035 mg of EE for the treatment of dysmenorrhea. “LUNABELL® tablets ULD” was developed to reduce the incidence of serious side effects by decreasing the amount of EE to 0.02 mg.

 Through the launch of “LUNABELL® tablets ULD,” together with “LUNABELL® tablets LD,” we hope to contribute to the improvement of patients’ QOL by providing the clinical settings with a new treatment option for dysmenorrhea.

 

* “LUNABELL® tablets LD”
Before receiving the marketing authorization of “LUNABELL® tablets ULD,” we have changed the product name of “LUNABELL® tablets” to “LUNABELL® tablets LD” and its indication to “dysmenorrhea,” the same as that of “LUNABELL® tablets ULD.”